FDA/Arthritis Foundation osteoarthritis drug development workshop recap: Assessment of long-term benefit.
Kim JS, Borges S, Clauw DJ, Conaghan PG, Felson DT, Fleming TR, Glaser R, Hart E, Hochberg M, Kim Y, Kraus VB, Lapteva L, Li X, Majumdar S, McAlindon TE, Mobasheri A, Neogi T, Roemer FW, Rothwell R, Shibuya R, Siegel J, Simon LS, Spindler KP, Nikolov NP.
Kim JS, et al. Among authors: hart e.
Semin Arthritis Rheum. 2022 Oct;56:152070. doi: 10.1016/j.semarthrit.2022.152070. Epub 2022 Jul 14.
Semin Arthritis Rheum. 2022.
PMID: 35870222
Free PMC article.
Review.
RESULTS: Speakers selected by the Planning Committee presented data on the current approach to assessment of OA therapies, biomarkers in OA drug development, and the assessment of disease progression and long-term benefit. CONCLUSIONS: Demonstrated by numerous failed clini …
RESULTS: Speakers selected by the Planning Committee presented data on the current approach to assessment of OA therapies, biomarkers in OA …